17-39974939-G-C
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_178171.5(GSDMA):āc.946G>Cā(p.Glu316Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000391 in 1,612,390 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.000020 ( 0 hom., cov: 32)
Exomes š: 0.000041 ( 1 hom. )
Consequence
GSDMA
NM_178171.5 missense
NM_178171.5 missense
Scores
1
6
12
Clinical Significance
Conservation
PhyloP100: 2.19
Genes affected
GSDMA (HGNC:13311): (gasdermin A) Predicted to enable phosphatidylinositol-4,5-bisphosphate binding activity; phosphatidylinositol-4-phosphate binding activity; and phosphatidylserine binding activity. Involved in apoptotic process. Located in perinuclear region of cytoplasm. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.19316444).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GSDMA | NM_178171.5 | c.946G>C | p.Glu316Gln | missense_variant | 10/12 | ENST00000301659.9 | NP_835465.2 | |
GSDMA | XM_006721832.4 | c.946G>C | p.Glu316Gln | missense_variant | 10/12 | XP_006721895.1 | ||
GSDMA | XM_017024502.3 | c.919G>C | p.Glu307Gln | missense_variant | 9/11 | XP_016879991.1 | ||
GSDMA | XM_011524651.4 | c.520G>C | p.Glu174Gln | missense_variant | 8/10 | XP_011522953.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GSDMA | ENST00000301659.9 | c.946G>C | p.Glu316Gln | missense_variant | 10/12 | 1 | NM_178171.5 | ENSP00000301659.4 | ||
GSDMA | ENST00000635792.1 | c.946G>C | p.Glu316Gln | missense_variant | 10/12 | 5 | ENSP00000490739.1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152196Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152196
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000404 AC: 1AN: 247416Hom.: 0 AF XY: 0.00000745 AC XY: 1AN XY: 134272
GnomAD3 exomes
AF:
AC:
1
AN:
247416
Hom.:
AF XY:
AC XY:
1
AN XY:
134272
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000411 AC: 60AN: 1460076Hom.: 1 Cov.: 31 AF XY: 0.0000386 AC XY: 28AN XY: 726320
GnomAD4 exome
AF:
AC:
60
AN:
1460076
Hom.:
Cov.:
31
AF XY:
AC XY:
28
AN XY:
726320
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152314Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74484
GnomAD4 genome
AF:
AC:
3
AN:
152314
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74484
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 22, 2023 | The c.946G>C (p.E316Q) alteration is located in exon 10 (coding exon 9) of the GSDMA gene. This alteration results from a G to C substitution at nucleotide position 946, causing the glutamic acid (E) at amino acid position 316 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
.;T
M_CAP
Benign
T
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;M
PrimateAI
Uncertain
T
PROVEAN
Benign
.;N
REVEL
Benign
Sift
Benign
.;T
Sift4G
Pathogenic
.;D
Polyphen
D;D
Vest4
0.52
MVP
0.16
MPC
0.42
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at